Unleashing CAR-T to target self-antigens

PrismCore delivers promising results

Unleashing CAR-T
Bio4t2's science is fueling new developments in CAR-T therapies for solid tumors, that previously held-back the field. PrismCore is able to produce CARs that are architecturally optimized to instill in T cells antigen density dependent response. The calibrated CAR-T specifically bind to self-antigens when they are over-expressed on the surface of malignant cells with the promise of a therapeutic effect.

Defeating solid tumors with PrismCore platform

View Video

More about the science of PrismCore

View Video
Bio4t2 LinkedIn
Bio4t2TM, PrismCoreTM, Bio-EngineTM and Bio-StrikeTM are trademarks of Bio4t2. Privacy Page »